A quantitative study of the in vitro binding of the C-terminal domain of p21 to PCNA: Affinity, stoichiometry, and thermodynamics

被引:74
作者
Zheleva, DI
Zhelev, NZ
Fischer, PM
Duff, SV
Warbrick, E
Blake, DG
Lane, DP
机构
[1] Cyclacel Ltd, Dundee DD1 5JJ, Scotland
[2] Univ Dundee, Dept Biochem, CRC Labs, Dundee DD1 4HN, Scotland
关键词
D O I
10.1021/bi992498r
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Proliferating cell nuclear antigen (PCNA) plays an essential role in DNA replication, repair, and control of cell proliferation, and its activity can be modulated by interaction with p21(Wa1/Cip1) [Cox, L. S., (1997) Trends Cell Biol. 7, 493-497]. This protein-protein interaction provides a particularly good model target for designing therapeutic agents to treat proliferative disorders such as cancer. In this study, the formation of complexes between PCNA and peptides derived from the C-terminus of p21 has been investigated at the molecular level and quantified using a competitive PCNA binding assay and isothermal titration calorimetry (ITC). The affinity constant for the interaction between p21 (141-160) peptide and PCNA has been determined to be 1.14 x 10(7) M-1, corresponding to a K-d Of 87.7 nM. Measurement of the interaction of truncation and substitution analogues based on the p21 (141-160) sequence with PCNA revealed that the N-terminal part (residues 141-152) of the above peptide is the minimum recognition motif, required for PCNA binding. Truncation of the C-terminal region p21 (153-160), though, inhibited significantly the ability of the peptides to compete with the full-length p21 (141-160) for binding to PCNA. Alanine mutation of Met 147 or Asp 149 completely abolished or significantly decreased, respectively, the level of the PCNA binding and the inhibition of SV40 DNA replication. Comparison of the data obtained by the competitive PCNA binding assay and the ITC measurements demonstrated the usefulness of this assay for screening for compounds that could modulate the PCNA-p21 interaction. Using this assay, we have screened rationally designed peptides for binding to PCNA and interruption of the PCNA-p21 (141-160) complex. As a result of this screening, we have identified a 16-residue peptide (consensus motif 1 peptide) with the following sequence: SAVLQKKITDYFHPKK. Consensus motif 1 peptide and p21 (141-160) have similar affinities for binding PCNA and abilities to inhibit in vitro replication of DNA originated from SV40. Such peptides could prove useful in assessing p21-mimetic strategies for cancer treatment.
引用
收藏
页码:7388 / 7397
页数:10
相关论文
共 58 条
[1]  
Bonfanti M, 1997, CANCER RES, V57, P1442
[2]   Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo [J].
Bottger, A ;
Bottger, V ;
Sparks, A ;
Liu, WL ;
Howard, SF ;
Lane, DP .
CURRENT BIOLOGY, 1997, 7 (11) :860-869
[3]   CYCLIN PCNA IS THE AUXILIARY PROTEIN OF DNA POLYMERASE-DELTA [J].
BRAVO, R ;
FRANK, R ;
BLUNDELL, PA ;
MACDONALDBRAVO, H .
NATURE, 1987, 326 (6112) :515-517
[4]  
BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698
[5]   p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells [J].
Cayrol, C ;
Knibiehler, M ;
Ducommun, B .
ONCOGENE, 1998, 16 (03) :311-320
[6]   A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo [J].
Chen, JJ ;
Peters, R ;
Saha, P ;
Lee, P ;
Theodoras, A ;
Pagano, M ;
Wagner, G ;
Dutta, A .
NUCLEIC ACIDS RESEARCH, 1996, 24 (09) :1727-1733
[7]   SEPARATE DOMAINS OF P21 INVOLVED IN THE INHIBITION OF CDK KINASE AND PCNA [J].
CHEN, JJ ;
JACKSON, PK ;
KIRSCHNER, MW ;
DUTTA, A .
NATURE, 1995, 374 (6520) :386-388
[8]   Who binds wins: competition for PCNA rings out cell-cycle changes [J].
Cox, LS .
TRENDS IN CELL BIOLOGY, 1997, 7 (12) :493-498
[9]   Inhibition of cyclin-dependent kinases by purine analogues - Crystal structure of human cdk2 complexed with roscovitine [J].
DeAzevedo, WF ;
Leclerc, S ;
Meijer, L ;
Havlicek, L ;
Strnad, M ;
Kim, SH .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2) :518-526
[10]   WAF1, A POTENTIAL MEDIATOR OF P53 TUMOR SUPPRESSION [J].
ELDEIRY, WS ;
TOKINO, T ;
VELCULESCU, VE ;
LEVY, DB ;
PARSONS, R ;
TRENT, JM ;
LIN, D ;
MERCER, WE ;
KINZLER, KW ;
VOGELSTEIN, B .
CELL, 1993, 75 (04) :817-825